Launch One Acquisition CORP

Launch One Acquisition Corp. shareholders approved an amendment to extend the deadline for completing a business combination from July 15, 2026, to January 15, 2027.

Launch One Acquisition Corp. has rescheduled its extraordinary general meeting to July 10, 2026, to vote on extending its business combination deadline.

Launch One Acquisition Corp. announced the appointment of Daniel Clifford Rogers to its Board of Directors and as Chair of the Audit Committee, replacing Dr. Risa Stack.

Launch One Acquisition Corp. has entered into a definitive Business Combination Agreement with Minovia Therapeutics Ltd., an Israeli mitochondrial therapy company, which will result in Minovia becoming a publicly traded company on Nasdaq under a new parent entity, Mito US One Ltd.

Launch One Acquisition Corp. and Minovia Therapeutics Ltd. have announced a definitive business combination agreement, valuing Minovia at $180 million, to create a Nasdaq-listed clinical-stage biotechnology company focused on mitochondrial therapies.

Launch One Acquisition Corp. will allow separate trading of its Class A ordinary shares and warrants starting September 3, 2024.

Launch One Acquisition Corp. reports on its Q2 2026 financial status, highlighting a significant extension of its business combination deadline to January 15, 2027, following substantial shareholder redemptions.

Launch One Acquisition Corp. reported a net income of $1.7 million for Q1 2026, but terminated its Minovia business combination and faces significant liquidity challenges with a July 2026 deadline.

Launch One Acquisition Corp. reports Q3 2025 net income of $2.01M, progresses Minovia merger, but faces significant liquidity and going concern doubts.

Launch One Acquisition Corp. reports progress on its Minovia Therapeutics merger, extending bridge financing timelines while facing a going concern warning due to liquidity needs.

Launch One Acquisition Corp. reports a net income of $2.3 million for the quarter ended March 31, 2025, driven by interest earned on trust account securities.

Launch One Acquisition Corp. reported a net income of $2.6 million for the quarter ending September 30, 2024, primarily driven by interest and unrealized gains on trust account investments.

Launch One Acquisition Corp. (LPAA) reported a net income of $8.3 million for 2025 but faces substantial doubt about its ability to continue as a going concern after terminating its planned business combination with Minovia Therapeutics Ltd.

Launch One Acquisition Corp. outlines its registered securities, including units, Class A ordinary shares, and public warrants, as of December 31, 2024, in its annual 10-K filing.

Launch One Acquisition Corp. secured up to $1 million in working capital from its sponsor to fund operations and business combination efforts, incurring significant debt costs.

Minovia Therapeutics announced two new U.S. patents, strengthening its mitochondrial augmentation therapy platform for primary mitochondrial and renal diseases.

Minovia Therapeutics, set to merge with Launch One Acquisition Corp., announced a $350,000 grant from Countdown for a Cure Foundation to develop novel mitochondrial blood-based biomarkers.

Minovia Therapeutics announced positive interim Phase 2 trial results for MNV-201 in Pearson Syndrome, showing a favorable safety profile and preliminary efficacy signals, alongside progress towards a business combination with Launch One Acquisition Corp.

Launch One Acquisition Corp. has entered into a definitive Business Combination Agreement with Minovia Therapeutics Ltd., an Israeli mitochondrial therapy company, which will result in Minovia becoming a publicly traded company on Nasdaq through a new parent entity, Mito US One Ltd. (Pubco).

Minovia Therapeutics announced that its lead investigational compound, MNV-201, received both Fast Track and Rare Pediatric Disease Designations from the FDA for the treatment of Pearson Syndrome, potentially accelerating its market entry and offering significant financial benefits.

Launch One Acquisition Corp. is seeking shareholder approval to extend its business combination deadline from July 15, 2026, to January 15, 2027.

Launch One Acquisition Corp. filed an amendment to its Form S-1 registration statement with the SEC on July 1, 2024, primarily to include certain exhibits related to its upcoming initial public offering.

Launch One Acquisition Corp., a blank check company, aims to raise $200 million in an IPO to pursue a business combination within the healthcare and life sciences sectors.

Mizuho Financial Group, Inc. has filed a Schedule 13G, reporting a 0.1% beneficial ownership of Launch One Acquisition Corp. common shares as of June 30, 2026.

Barclays PLC has filed an amended Schedule 13G, indicating it no longer beneficially owns any common stock in Launch One Acquisition Corp.

MMCAP International Inc. SPC and MM Asset Management Inc. jointly reported beneficial ownership of 6.4% of Launch One Acquisition Corp.'s Class A Ordinary Shares.

MMCAP International Inc. SPC and MM Asset Management Inc. jointly reported beneficial ownership of 8.1% of Fifth Era Acquisition Corp I's Class A Ordinary Shares as of December 31, 2025.

Mizuho Financial Group, Inc. has reported a 6.2% beneficial ownership stake in Launch One Acquisition Corp. through a Schedule 13G filing.

W. R. Berkley Corporation and its subsidiary, Berkley Insurance Company, have disclosed a passive 6.2% beneficial ownership stake in Launch One Acquisition Corp.'s Class A Ordinary Shares.